Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects

An Open-Label, Single-Dose, Parallel Group Study to Evaluate the Effects of Age and Gender on the Pharmacokinetics, Safety, and Tolerability of HCV-796 Administered Orally to Healthy Subjects

This study is an open-label, single-dose, parallel group study to evaluate the effects of age and gender on the pharmacokinetics, safety, and tolerability of HCV-796 administered orally to healthy subjects.

Inclusion:

• Men or nonlactating and nonpregnant women, aged 18 to 45, and >65 years.
• Men must agree to practice barrier contraception for 12 weeks after the last test article administration.
• Estimated (calculated) creatinine clearance must be within the age-appropriate normal range.

Exclusion:

• History of seizures.
• History of rhabdomyolysis.
• History of thyroid disease.